Cargando…
Contemporary survival and anticoagulation of patients with atrial fibrillation: A community based cohort study in China
BACKGROUNDS: The understanding of death in patients with atrial fibrillation (AF) in China is limited. This study aimed to assess the contemporary survival of AF patients in China and to explore risk factors for deaths. METHODS: This was a prospective community-based cohort study including 559 AF pa...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363600/ https://www.ncbi.nlm.nih.gov/pubmed/35966522 http://dx.doi.org/10.3389/fcvm.2022.911393 |
_version_ | 1784764961354940416 |
---|---|
author | Wei, Yong Zeng, Qingye Cai, Lidong Wang, Xingjie Wang, Bin Shen, Chaoying Li, Chao Wang, Caihong Shen, Yahong Yang, Shunhong Wu, Xiaoyu Liu, Yan Xu, Juan Lu, Xiaofeng Chen, Songwen Zhou, Genqing Liu, Shaowen |
author_facet | Wei, Yong Zeng, Qingye Cai, Lidong Wang, Xingjie Wang, Bin Shen, Chaoying Li, Chao Wang, Caihong Shen, Yahong Yang, Shunhong Wu, Xiaoyu Liu, Yan Xu, Juan Lu, Xiaofeng Chen, Songwen Zhou, Genqing Liu, Shaowen |
author_sort | Wei, Yong |
collection | PubMed |
description | BACKGROUNDS: The understanding of death in patients with atrial fibrillation (AF) in China is limited. This study aimed to assess the contemporary survival of AF patients in China and to explore risk factors for deaths. METHODS: This was a prospective community-based cohort study including 559 AF patients, who were followed-up from July 2015 to December 2020. RESULTS: During 66-month follow-up, there were 200 deaths (56.5% cardiovascular, 40.0% non-cardiovascular, and 3.5% unknown causes) among 559 AF patients with the median age of 76 years. The top three causes of death were heart failure (33.0%), ischemic stroke (17.0%) and cancer (16.5%). Multivariate Cox regression analysis indicated baseline variables positively associated with all-cause death were age (HR: 1.10, 95% CI: 1.08–1.13), AF subtype (HR: 1.37, 95% CI: 1.08–1.73), prior myocardial infarction (HR: 3.40, 95% CI: 1.48–7.78), previous tumor (HR: 2.61, 95% CI: 1.37–4.98), hypoglycemic therapy at baseline (HR: 1.81, 95% CI: 1.13–2.91), but body weight (HR: 0.98, 95% CI: 0.97–1.00) and use of calcium channel blocker (CCB) (HR: 0.62, 95% CI: 0.41–0.95) played a protective role to all-cause death. Of patients who were alive at the end of follow-up, 24.0% were on oral anticoagulants (OAC) alone, 4.5% on dual antithrombotic therapy, 33.1% on antiplatelet agents alone and 38.4% weren't on any antithrombotic medication. CONCLUSION: Ischemic stroke still remains one of the leading causes of death and OAC is seriously underused in AF patients in China. Independent risk factors for death are age, AF subtype, previous tumor, prior myocardial infarction, hypoglycemic therapy, low body weight and no CCB use. CLINICAL TRIAL REGISTRATION: http://www.chictr.org.cn/ (ChiCTR-ICR-15007036). |
format | Online Article Text |
id | pubmed-9363600 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93636002022-08-11 Contemporary survival and anticoagulation of patients with atrial fibrillation: A community based cohort study in China Wei, Yong Zeng, Qingye Cai, Lidong Wang, Xingjie Wang, Bin Shen, Chaoying Li, Chao Wang, Caihong Shen, Yahong Yang, Shunhong Wu, Xiaoyu Liu, Yan Xu, Juan Lu, Xiaofeng Chen, Songwen Zhou, Genqing Liu, Shaowen Front Cardiovasc Med Cardiovascular Medicine BACKGROUNDS: The understanding of death in patients with atrial fibrillation (AF) in China is limited. This study aimed to assess the contemporary survival of AF patients in China and to explore risk factors for deaths. METHODS: This was a prospective community-based cohort study including 559 AF patients, who were followed-up from July 2015 to December 2020. RESULTS: During 66-month follow-up, there were 200 deaths (56.5% cardiovascular, 40.0% non-cardiovascular, and 3.5% unknown causes) among 559 AF patients with the median age of 76 years. The top three causes of death were heart failure (33.0%), ischemic stroke (17.0%) and cancer (16.5%). Multivariate Cox regression analysis indicated baseline variables positively associated with all-cause death were age (HR: 1.10, 95% CI: 1.08–1.13), AF subtype (HR: 1.37, 95% CI: 1.08–1.73), prior myocardial infarction (HR: 3.40, 95% CI: 1.48–7.78), previous tumor (HR: 2.61, 95% CI: 1.37–4.98), hypoglycemic therapy at baseline (HR: 1.81, 95% CI: 1.13–2.91), but body weight (HR: 0.98, 95% CI: 0.97–1.00) and use of calcium channel blocker (CCB) (HR: 0.62, 95% CI: 0.41–0.95) played a protective role to all-cause death. Of patients who were alive at the end of follow-up, 24.0% were on oral anticoagulants (OAC) alone, 4.5% on dual antithrombotic therapy, 33.1% on antiplatelet agents alone and 38.4% weren't on any antithrombotic medication. CONCLUSION: Ischemic stroke still remains one of the leading causes of death and OAC is seriously underused in AF patients in China. Independent risk factors for death are age, AF subtype, previous tumor, prior myocardial infarction, hypoglycemic therapy, low body weight and no CCB use. CLINICAL TRIAL REGISTRATION: http://www.chictr.org.cn/ (ChiCTR-ICR-15007036). Frontiers Media S.A. 2022-07-27 /pmc/articles/PMC9363600/ /pubmed/35966522 http://dx.doi.org/10.3389/fcvm.2022.911393 Text en Copyright © 2022 Wei, Zeng, Cai, Wang, Wang, Shen, Li, Wang, Shen, Yang, Wu, Liu, Xu, Lu, Chen, Zhou and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Wei, Yong Zeng, Qingye Cai, Lidong Wang, Xingjie Wang, Bin Shen, Chaoying Li, Chao Wang, Caihong Shen, Yahong Yang, Shunhong Wu, Xiaoyu Liu, Yan Xu, Juan Lu, Xiaofeng Chen, Songwen Zhou, Genqing Liu, Shaowen Contemporary survival and anticoagulation of patients with atrial fibrillation: A community based cohort study in China |
title | Contemporary survival and anticoagulation of patients with atrial fibrillation: A community based cohort study in China |
title_full | Contemporary survival and anticoagulation of patients with atrial fibrillation: A community based cohort study in China |
title_fullStr | Contemporary survival and anticoagulation of patients with atrial fibrillation: A community based cohort study in China |
title_full_unstemmed | Contemporary survival and anticoagulation of patients with atrial fibrillation: A community based cohort study in China |
title_short | Contemporary survival and anticoagulation of patients with atrial fibrillation: A community based cohort study in China |
title_sort | contemporary survival and anticoagulation of patients with atrial fibrillation: a community based cohort study in china |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363600/ https://www.ncbi.nlm.nih.gov/pubmed/35966522 http://dx.doi.org/10.3389/fcvm.2022.911393 |
work_keys_str_mv | AT weiyong contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina AT zengqingye contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina AT cailidong contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina AT wangxingjie contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina AT wangbin contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina AT shenchaoying contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina AT lichao contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina AT wangcaihong contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina AT shenyahong contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina AT yangshunhong contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina AT wuxiaoyu contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina AT liuyan contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina AT xujuan contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina AT luxiaofeng contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina AT chensongwen contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina AT zhougenqing contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina AT liushaowen contemporarysurvivalandanticoagulationofpatientswithatrialfibrillationacommunitybasedcohortstudyinchina |